Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipratropium bromide + levosalbutamol (Pristine Pearl Pharma)
- Development stage
- Phase 4
- Lead developer
- Pristine Pearl Pharma
- Modality
- Small Molecules
- Administration
- Inhalation, Intranasal
01
Overview
Duoprl is a combination inhalation therapy marketed by Pristine Pearl Pharma, primarily used for the treatment and management of chronic obstructive pulmonary disease (COPD) and asthma. It is formulated as respules for nebulization and contains two active bronchodilating agents: ipratropium bromide, a short-acting anticholinergic (muscarinic antagonist), and levosalbutamol (levalbuterol), a short-acting beta-2 adrenergic receptor agonist. Together, these components work synergistically to relax bronchial smooth muscle, reduce mucus secretion, and widen the airways, thereby improving airflow and relieving symptoms such as wheezing, shortness of breath, and chest tightness.
- Brand names
- DuoprlDuoprl LDNew Duoprl
- Other names
- ipratropium + levosalbutamolipratropium bromide + levosalbutamollevosalbutamol + ipratropiumlevosalbutamol + ipratropium bromide
02
Targets
ADRB1 (β1)ADRB3 (β3)CHRM2 (Muscarinic acetylcholine receptor M2)CHRM3 (M3)ADRB2 (β2)M1 (Muscarinic acetylcholine receptor M1)
Beyond the preview
Go deeper on ipratropium bromide + levosalbutamol (Pristine Pearl Pharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipratropium bromide + levosalbutamol (Pristine Pearl Pharma).